September 8, 2011 | Amira Pharmaceuticals sold an early stage drug to Bristol-Myers for $325 million upfront cash plus milestone payments. So how did they do it? "A combination of really rigorous science, one particularly hard-nosed business decision, and some excellent timing." Xconomy